Sabine Hellwig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sabine Hellwig has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
Philipp T. Meyer
University of Freiburg
9 shared publications- Lars Frings
Department of Nuclear Medicine, Medical Center - Faculty of Medicine, University of Freiburg, Freiburg, Germany
7 shared publications - Ralph Buchert
Universitätsklinikum Hamburg-Eppendorf
5 shared publications - Werner Vach
Center for Muscle and Joint Health, Department of Sport Sciences and Clinical Biomechanics, University of Southern Denmark, Odense M, Denmark
4 shared publications Bernhard Hellwig
From the Departments of Neurology (S.H., F.A., M.R., B.H., C. Weiller, C. Winkler, O.T.), Psychiatry and Psychotherapy (S.H.), Nuclear Medicine (A.K., T.S.S., W.A.W., P.T.M.), and Clinical Epidemiology, Institute of Medical Biometry and Medical Informatics (W.V.), University of Freiburg; Department of Nuclear Medicine (R.B.), Charité Universitätsmedizin Berlin; Department of Nuclear Medicine (O.H.W.), University Hospital Aachen; and Department of Psychiatry and Psychotherapy (O.T.), Johannes...
3 shared publications- Cornelius Weiller
Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
3 shared publications
Latest Publications
- 8 May 2025
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 228 (4) , 332-339
[ 18 F]Fluorodeoxyglucose position emission tomography for differential diagnosis of depressive cognitive impairment: incremental value compared with clinical diagnosis
Background: Assessment of regional glucose metabolism by [ 18 F]fluorodeoxyglucose position emission tomography ([ 18 F]FDG PET) serves as a biomarker for differential diagnosis of dementia. Conversely, depressive cognitive impairment shows no abnormalities on cerebral [ 18 F]FDG PET. Aims: This study validates the diagnostic value of [ 18 F]FDG PET in addition to clinical diagnosis in a real-life gerontopsychiatric clinical population. Method: Ninety-eight consecutive patients with depression and cognitive impairment were included. Baseline clinical diagnoses were independently established before and after disclosure of [ 18 F]FDG PET, and dichotomised into neurodegenerative or non-neurodegenerative diseases (level 1). Subsequently, neurodegenerative cases were allocated to diagnostic subgroups (Alzheimer’s disease, Lewy body diseases, frontotemporal lobar degeneration, neurodegenerative other; level 2). An interdisciplinary, biomarker-supported consensus diagnosis after a median follow-up of 6.6 month after [ 18 F]FDG PET served as reference. Changes of clinical diagnoses and diagnostic accuracy were assessed. Results: After disclosure of [ 18 F]FDG PET, level-1 clinical diagnoses changed in 23% (95% CI 16–33%) of cases, improving the diagnostic accuracy from 72% (95% CI 62–81%) to 92% (95% CI 84–96%) ( P < 0.001). [ 18 F]FDG PET was of particular value for exclusion of neurodegenerative disease. Concerning level-2 decisions, the clinical diagnoses changed in 30% (95% CI 21–40%) of cases, increasing its accuracy from 64% (95% CI 54–74%) to 85% (95% CI 76–91%) ( P < 0.001). A major fraction of incorrect level-2 diagnoses comprised Alzheimer’s disease misdiagnosed as Lewy body diseases. Conclusions: [ 18 F]FDG PET provides a significant incremental diagnostic value beyond the clinical diagnosis in depressive cognitive impairment. Thus, [ 18 F]FDG PET should be considered in the diagnostic work-up of patients with mental disorders and cognitive impairment.
- 8 May 2025
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 228 (4) , 332-339
[ 18 F]Fluorodeoxyglucose position emission tomography for differential diagnosis of depressive cognitive impairment: incremental value compared with clinical diagnosis
Background: Assessment of regional glucose metabolism by [ 18 F]fluorodeoxyglucose position emission tomography ([ 18 F]FDG PET) serves as a biomarker for differential diagnosis of dementia. Conversely, depressive cognitive impairment shows no abnormalities on cerebral [ 18 F]FDG PET. Aims: This study validates the diagnostic value of [ 18 F]FDG PET in addition to clinical diagnosis in a real-life gerontopsychiatric clinical population. Method: Ninety-eight consecutive patients with depression and cognitive impairment were included. Baseline clinical diagnoses were independently established before and after disclosure of [ 18 F]FDG PET, and dichotomised into neurodegenerative or non-neurodegenerative diseases (level 1). Subsequently, neurodegenerative cases were allocated to diagnostic subgroups (Alzheimer’s disease, Lewy body diseases, frontotemporal lobar degeneration, neurodegenerative other; level 2). An interdisciplinary, biomarker-supported consensus diagnosis after a median follow-up of 6.6 month after [ 18 F]FDG PET served as reference. Changes of clinical diagnoses and diagnostic accuracy were assessed. Results: After disclosure of [ 18 F]FDG PET, level-1 clinical diagnoses changed in 23% (95% CI 16–33%) of cases, improving the diagnostic accuracy from 72% (95% CI 62–81%) to 92% (95% CI 84–96%) ( P < 0.001). [ 18 F]FDG PET was of particular value for exclusion of neurodegenerative disease. Concerning level-2 decisions, the clinical diagnoses changed in 30% (95% CI 21–40%) of cases, increasing its accuracy from 64% (95% CI 54–74%) to 85% (95% CI 76–91%) ( P < 0.001). A major fraction of incorrect level-2 diagnoses comprised Alzheimer’s disease misdiagnosed as Lewy body diseases. Conclusions: [ 18 F]FDG PET provides a significant incremental diagnostic value beyond the clinical diagnosis in depressive cognitive impairment. Thus, [ 18 F]FDG PET should be considered in the diagnostic work-up of patients with mental disorders and cognitive impairment.
- 21 June 2023
- Published by Springer Nature in Der Nervenarzt
- Vol. 94 (7) , 647-654
Angst- und Abhängigkeitserkrankungen – Fokus Alkohol und Cannabis
Zusammenfassung Angsterkrankungen sind mit einer 12-Monats-Prävalenz von 14 % häufig, neigen zu Chronizität und weisen eine hohe Komorbidität mit Abhängigkeitserkrankungen auf. Angst- wie auch Abhängigkeitserkrankungen gehen mit einer ausgeprägten individuellen wie auch sozioökonomischen Belastung einher. Der vorliegende Artikel gibt eine Übersicht zu epidemiologischen, ätiologischen und klinischen Aspekten der Doppeldiagnose von Angst- und Abhängigkeitserkrankungen mit besonderem Fokus auf Alkohol und Cannabis. Die Therapie umfasst neben nichtpharmakologischen Strategien – vor allem der kognitiven Verhaltenstherapie in Verbindung mit Elementen des Motivational Interviewing (MI) – das pharmakologische Management mit Antidepressiva. Allerdings wird der Gebrauch von SSRIs („selective serotonin reuptake inhibitors“)/SNRIs („serotonin and noradrenaline reuptake inhibitors“) nicht uneingeschränkt empfohlen. Der Einsatz von Gabapentinoiden bedarf aufgrund von Missbrauchs- und Abhängigkeitspotenzial bei Abhängigkeitserkrankungen einer sorgfältigen Nutzen-Risiko-Abwägung. Benzodiazepine sind ausschließlich dem Krisenmanagement vorbehalten. Die rasche Diagnosestellung und eine beide Erkrankungen targetierende Therapie sind essenziell für eine erfolgreiche Behandlung einer komorbiden Angst- und Abhängigkeitserkrankung.
- 21 June 2023
- Published by Springer Nature in Der Nervenarzt
- Vol. 94 (7) , 647-654
Angst- und Abhängigkeitserkrankungen – Fokus Alkohol und Cannabis
Zusammenfassung Angsterkrankungen sind mit einer 12-Monats-Prävalenz von 14 % häufig, neigen zu Chronizität und weisen eine hohe Komorbidität mit Abhängigkeitserkrankungen auf. Angst- wie auch Abhängigkeitserkrankungen gehen mit einer ausgeprägten individuellen wie auch sozioökonomischen Belastung einher. Der vorliegende Artikel gibt eine Übersicht zu epidemiologischen, ätiologischen und klinischen Aspekten der Doppeldiagnose von Angst- und Abhängigkeitserkrankungen mit besonderem Fokus auf Alkohol und Cannabis. Die Therapie umfasst neben nichtpharmakologischen Strategien – vor allem der kognitiven Verhaltenstherapie in Verbindung mit Elementen des Motivational Interviewing (MI) – das pharmakologische Management mit Antidepressiva. Allerdings wird der Gebrauch von SSRIs („selective serotonin reuptake inhibitors“)/SNRIs („serotonin and noradrenaline reuptake inhibitors“) nicht uneingeschränkt empfohlen. Der Einsatz von Gabapentinoiden bedarf aufgrund von Missbrauchs- und Abhängigkeitspotenzial bei Abhängigkeitserkrankungen einer sorgfältigen Nutzen-Risiko-Abwägung. Benzodiazepine sind ausschließlich dem Krisenmanagement vorbehalten. Die rasche Diagnosestellung und eine beide Erkrankungen targetierende Therapie sind essenziell für eine erfolgreiche Behandlung einer komorbiden Angst- und Abhängigkeitserkrankung.
- 23 May 2022
- Published by Springer Nature in Der Nervenarzt
- Vol. 93 (8) , 788-796
Post-COVID-Syndrom – Fokus Fatigue
Zusammenfassung Die Weltgesundheitsorganisation (WHO) definiert Post-COVID-19(„coronavirus disease 2019“) als Zustand, der bei Personen mit einer anamnestisch wahrscheinlichen oder bestätigten SARS-CoV-2(„severe acute respiratory syndrome coronavirus type 2“)-Infektion 3 Monate nach Beginn der COVID-19-Symptome und mindestens 2 Monate andauernd vorhanden ist und durch eine alternative Diagnose nicht erklärbar ist. Kernsymptome des Post-COVID-Syndroms umfassen Atemnot, Fatigue und kognitive Dysfunktion, welche das alltägliche Funktionsniveau beeinflussen. Neuropsychiatrische Spätfolgen sind bei COVID-19-Patienten mit Inzidenzraten von über 30 % häufig. Neben den genannten Kernsymptomen zeigen Schlafstörungen, Depression und Angsterkrankungen erhöhte Inzidenzen. Nach gegenwärtiger Meinung werden assoziierte neuropsychiatrische Symptome sowohl unter dem Begriff Post-COVID-Syndrom subsumiert, aber auch als Komorbiditäten interpretiert, welche die Manifestation eines Post-COVID-Syndroms begünstigen können. So zeigt das Kernsymptom Fatigue Symptomüberlappung und Komorbidität mit psychischen Erkrankungen. Bildgebungsstudien deuten auf ein organisches Korrelat der Fatigue bei Post-COVID-Patienten hin, darüber hinaus wurden psychosoziale Aspekte und psychiatrische Komorbiditäten wie Depression und Angsterkrankungen als modulierende und damit potenziell behandelbare Faktoren identifiziert. Die Therapie der Fatigue umfasst neben dem pharmakologischen Management mit u. a. Stimulanzien und Antidepressiva auch nichtpharmakologische Strategien, hier vor allem die kognitive Verhaltenstherapie sowie körper- und bewegungsfokussierte Interventionen. Die Evidenz hierfür erwächst aus Metaanalysen bei tumorassoziierter oder postviraler Fatigue.
- 23 May 2022
- Published by Springer Nature in Der Nervenarzt
- Vol. 93 (8) , 788-796
Post-COVID-Syndrom – Fokus Fatigue
Zusammenfassung Die Weltgesundheitsorganisation (WHO) definiert Post-COVID-19(„coronavirus disease 2019“) als Zustand, der bei Personen mit einer anamnestisch wahrscheinlichen oder bestätigten SARS-CoV-2(„severe acute respiratory syndrome coronavirus type 2“)-Infektion 3 Monate nach Beginn der COVID-19-Symptome und mindestens 2 Monate andauernd vorhanden ist und durch eine alternative Diagnose nicht erklärbar ist. Kernsymptome des Post-COVID-Syndroms umfassen Atemnot, Fatigue und kognitive Dysfunktion, welche das alltägliche Funktionsniveau beeinflussen. Neuropsychiatrische Spätfolgen sind bei COVID-19-Patienten mit Inzidenzraten von über 30 % häufig. Neben den genannten Kernsymptomen zeigen Schlafstörungen, Depression und Angsterkrankungen erhöhte Inzidenzen. Nach gegenwärtiger Meinung werden assoziierte neuropsychiatrische Symptome sowohl unter dem Begriff Post-COVID-Syndrom subsumiert, aber auch als Komorbiditäten interpretiert, welche die Manifestation eines Post-COVID-Syndroms begünstigen können. So zeigt das Kernsymptom Fatigue Symptomüberlappung und Komorbidität mit psychischen Erkrankungen. Bildgebungsstudien deuten auf ein organisches Korrelat der Fatigue bei Post-COVID-Patienten hin, darüber hinaus wurden psychosoziale Aspekte und psychiatrische Komorbiditäten wie Depression und Angsterkrankungen als modulierende und damit potenziell behandelbare Faktoren identifiziert. Die Therapie der Fatigue umfasst neben dem pharmakologischen Management mit u. a. Stimulanzien und Antidepressiva auch nichtpharmakologische Strategien, hier vor allem die kognitive Verhaltenstherapie sowie körper- und bewegungsfokussierte Interventionen. Die Evidenz hierfür erwächst aus Metaanalysen bei tumorassoziierter oder postviraler Fatigue.
- 14 April 2022
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 61 (02) , 159-160
Klinik, Metabolismus und Überleben beim rechts-homologen PET-Befund einer svPPA
Ziel/Aim Während die linksseitige Neurodegeneration des Temporalpols (TP) häufig mit dem klinischen Syndrom einer semantischen Variante der primär progredienten Aphasie (svPPA) einhergeht, ist die rechtsseitige Variante weitaus weniger gut charakterisiert. Methodik/Methods Wir identifizierten Patienten mit im Vordergrund stehendem Hypometabolismus des TP, die 2009 bis 2020 eine FDG-PET zur Demenzabklärung erhielten und einen negative Amyloid-PET aufwiesen (sofern verfügbar). Der normalisierte Metabolismus (Referenz: Hirnparenchym) wurde in AAL3-Atlas-basierten ROI ausgelesen. Patienten wurden anhand der Asymmetrie des Metabolismus des mittleren TP in drei Gruppen eingeteilt (Hypometabolismus links- oder rechtsbetont bzw. symmetrisch beidseitig: LTP, RTP, BTP). Die Gruppen wurden hinsichtlich (1) Metabolismus in 86 kortikalen ROI (im Vgl. zu einer Kontrollkohorte, N=80), (2) kognitiver Testleistung (CERAD) und (3) Überlebensdauer nach FDG-PET untersucht. Ergebnisse/Results 39 Patienten (Alter 66,9±7,0) erfüllten die Einschlusskriterien (20 LTP, 9 BTP, 10 RTP; Amyloid-PET in n=20). Die Gruppen unterschieden sich nicht hinsichtlich Symptomdauer. (1) Ein Hypometabolismus zeigte sich bei LTP v.a. links temporal, bei BTP lediglich in beiden mittleren TP-ROI, bei RTP hingegen in 7 rechts- und 2 linksseitigen temporalen ROI, zudem in 4 orbitofrontalen ROI (p<0.05, Bonferroni-korrigiert [bc]). (2) Kognitive Defizite zeigten alle drei Gruppen in Benennen, semantischer Flüssigkeit, und Verbalgedächtnis, RTP und BTP zudem im visuellen Gedächtnis (p<0.05, bc). (3) Bei N=32 waren Überlebensdaten verfügbar (n=13 verstorben). RTP zeigten ein signifikant kürzeres medianes Überleben als LTP (5,7 vs. 8,3 J.; HR=5,4 [95% C.I. 1,1 – 27,1]; altersadjustiertes Cox-Modell). Schlussfolgerungen/Conclusions RTP unterscheiden sich von BTP und LTP durch einen ausgedehnteren Hypometabolismus, der auch die Gegenseite und frontale Regionen umfasst. Das kognitive Leistungsprofil unterscheidet sich bei zusätzlichen visuellen Gedächtnisdefiziten kaum von LTP. Das Überleben ist bei RTP kürzer als bei LTP. Publication Date: 14 April 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2022
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 61 (02) , 159-160
Klinik, Metabolismus und Überleben beim rechts-homologen PET-Befund einer svPPA
Ziel/Aim Während die linksseitige Neurodegeneration des Temporalpols (TP) häufig mit dem klinischen Syndrom einer semantischen Variante der primär progredienten Aphasie (svPPA) einhergeht, ist die rechtsseitige Variante weitaus weniger gut charakterisiert. Methodik/Methods Wir identifizierten Patienten mit im Vordergrund stehendem Hypometabolismus des TP, die 2009 bis 2020 eine FDG-PET zur Demenzabklärung erhielten und einen negative Amyloid-PET aufwiesen (sofern verfügbar). Der normalisierte Metabolismus (Referenz: Hirnparenchym) wurde in AAL3-Atlas-basierten ROI ausgelesen. Patienten wurden anhand der Asymmetrie des Metabolismus des mittleren TP in drei Gruppen eingeteilt (Hypometabolismus links- oder rechtsbetont bzw. symmetrisch beidseitig: LTP, RTP, BTP). Die Gruppen wurden hinsichtlich (1) Metabolismus in 86 kortikalen ROI (im Vgl. zu einer Kontrollkohorte, N=80), (2) kognitiver Testleistung (CERAD) und (3) Überlebensdauer nach FDG-PET untersucht. Ergebnisse/Results 39 Patienten (Alter 66,9±7,0) erfüllten die Einschlusskriterien (20 LTP, 9 BTP, 10 RTP; Amyloid-PET in n=20). Die Gruppen unterschieden sich nicht hinsichtlich Symptomdauer. (1) Ein Hypometabolismus zeigte sich bei LTP v.a. links temporal, bei BTP lediglich in beiden mittleren TP-ROI, bei RTP hingegen in 7 rechts- und 2 linksseitigen temporalen ROI, zudem in 4 orbitofrontalen ROI (p<0.05, Bonferroni-korrigiert [bc]). (2) Kognitive Defizite zeigten alle drei Gruppen in Benennen, semantischer Flüssigkeit, und Verbalgedächtnis, RTP und BTP zudem im visuellen Gedächtnis (p<0.05, bc). (3) Bei N=32 waren Überlebensdaten verfügbar (n=13 verstorben). RTP zeigten ein signifikant kürzeres medianes Überleben als LTP (5,7 vs. 8,3 J.; HR=5,4 [95% C.I. 1,1 – 27,1]; altersadjustiertes Cox-Modell). Schlussfolgerungen/Conclusions RTP unterscheiden sich von BTP und LTP durch einen ausgedehnteren Hypometabolismus, der auch die Gegenseite und frontale Regionen umfasst. Das kognitive Leistungsprofil unterscheidet sich bei zusätzlichen visuellen Gedächtnisdefiziten kaum von LTP. Das Überleben ist bei RTP kürzer als bei LTP. Publication Date: 14 April 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 16 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (2) , 959
Functional Selectivity of Coumarin Derivates Acting via GPR55 in Neuroinflammation
Anti-neuroinflammatory treatment has gained importance in the search for pharmacological treatments of different neurological and psychiatric diseases, such as depression, schizophrenia, Parkinson’s disease, and Alzheimer’s disease. Clinical studies demonstrate a reduction of the mentioned diseases’ symptoms after the administration of anti-inflammatory drugs. Novel coumarin derivates have been shown to elicit anti-neuroinflammatory effects via G-protein coupled receptor GPR55, with possibly reduced side-effects compared to the known anti-inflammatory drugs. In this study, we, therefore, evaluated the anti-inflammatory capacities of the two novel coumarin-based compounds, KIT C and KIT H, in human neuroblastoma cells and primary murine microglia. Both compounds reduced PGE2-concentrations likely via the inhibition of COX-2 synthesis in SK-N-SH cells but only KIT C decreased PGE2-levels in primary microglia. The examination of other pro- and anti-inflammatory parameters showed varying effects of both compounds. Therefore, the differences in the effects of KIT C and KIT H might be explained by functional selectivity as well as tissue- or cell-dependent expression and signal pathways coupled to GPR55. Understanding the role of chemical residues in functional selectivity and specific cell- and tissue-targeting might open new therapeutic options in pharmacological drug development and might improve the treatment of the mentioned diseases by intervening in an early step of their pathogenesis.
- 16 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (2) , 959
Open AccessFunctional Selectivity of Coumarin Derivates Acting via GPR55 in Neuroinflammation
Anti-neuroinflammatory treatment has gained importance in the search for pharmacological treatments of different neurological and psychiatric diseases, such as depression, schizophrenia, Parkinson’s disease, and Alzheimer’s disease. Clinical studies demonstrate a reduction of the mentioned diseases’ symptoms after the administration of anti-inflammatory drugs. Novel coumarin derivates have been shown to elicit anti-neuroinflammatory effects via G-protein coupled receptor GPR55, with possibly reduced side-effects compared to the known anti-inflammatory drugs. In this study, we, therefore, evaluated the anti-inflammatory capacities of the two novel coumarin-based compounds, KIT C and KIT H, in human neuroblastoma cells and primary murine microglia. Both compounds reduced PGE2-concentrations likely via the inhibition of COX-2 synthesis in SK-N-SH cells but only KIT C decreased PGE2-levels in primary microglia. The examination of other pro- and anti-inflammatory parameters showed varying effects of both compounds. Therefore, the differences in the effects of KIT C and KIT H might be explained by functional selectivity as well as tissue- or cell-dependent expression and signal pathways coupled to GPR55. Understanding the role of chemical residues in functional selectivity and specific cell- and tissue-targeting might open new therapeutic options in pharmacological drug development and might improve the treatment of the mentioned diseases by intervening in an early step of their pathogenesis.
- Open Access
- 7 May 2019
- Published by Springer Nature in EJNMMI Research
- Vol. 9 (1) , 1-13
Diagnostic performance of the specific uptake size index for semi-quantitative analysis of I-123-FP-CIT SPECT: harmonized multi-center research setting versus typical clinical single-camera setting
The specific uptake size index (SUSI) of striatal FP-CIT uptake is independent of spatial resolution in the SPECT image, in contrast to the specific binding ratio (SBR). This suggests that the SUSI is particularly appropriate for multi-site/multi-camera settings in which camera-specific effects increase inter-subject variability of spatial resolution. However, the SUSI is sensitive to inter-subject variability of striatum size. Furthermore, it might be more sensitive to errors of the estimate of non-displaceable FP-CIT binding. This study compared SUSI and SBR in the multi-site/multi-camera (MULTI) setting of a prospective multi-center study and in a mono-site/mono-camera (MONO) setting representative of clinical routine. The MULTI setting included patients with Parkinson’s disease (PD, n = 438) and healthy controls (n = 207) from the Parkinson Progression Marker Initiative. The MONO setting included 122 patients from routine clinical patient care in whom FP-CIT SPECT had been performed with the same double-head SPECT system according to the same acquisition and reconstruction protocol. Patients were categorized as “neurodegenerative” (n = 84) or “non-neurodegenerative” (n = 38) based on follow-up data. FP-CIT SPECTs were stereotactically normalized to MNI space. SUSI and SBR were computed for caudate, putamen, and whole striatum using unilateral ROIs predefined in MNI space. SUSI analysis was repeated in native patient space in the MONO setting. The area (AUC) under the ROC curve for identification of PD/“neurodegenerative” cases was used as performance measure. In both settings, the highest AUC was achieved by the putamen (minimum over both hemispheres), independent of the semi-quantitative method (SUSI or SBR). The putaminal SUSI provided slightly better performance with ROI analysis in MNI space compared to patient space (AUC = 0.969 vs. 0.961, p = 0.129). The SUSI (computed in MNI space) performed slightly better than the SBR in the MULTI setting (AUC = 0.993 vs. 0.991, p = 0.207) and slightly worse in the MONO setting (AUC = 0.969 vs. AUC = 0.976, p = 0.259). There was a trend toward larger AUC difference between SUSI and SBR in the MULTI setting compared to the MONO setting (p = 0.073). Variability of voxel intensity in the reference region was larger in misclassified cases compared to correctly classified cases for both SUSI and SBR (MULTI setting: p = 0.007 and p = 0.012, respectively). The SUSI is particularly useful in MULTI settings. SPECT images should be stereotactically normalized prior to SUSI analysis. The putaminal SUSI provides better diagnostic performance than the SUSI of the whole striatum. Errors of the estimate of non-displaceable count density in the reference region can cause misclassification by both SUSI and SBR, particularly in borderline cases. These cases might be identified by visual checking FP-CIT uptake in the reference region for particularly high variability.
- 7 May 2019
- Published by Springer Nature in EJNMMI Research
- Vol. 9 (1) , 1-13
Open AccessDiagnostic performance of the specific uptake size index for semi-quantitative analysis of I-123-FP-CIT SPECT: harmonized multi-center research setting versus typical clinical single-camera setting
The specific uptake size index (SUSI) of striatal FP-CIT uptake is independent of spatial resolution in the SPECT image, in contrast to the specific binding ratio (SBR). This suggests that the SUSI is particularly appropriate for multi-site/multi-camera settings in which camera-specific effects increase inter-subject variability of spatial resolution. However, the SUSI is sensitive to inter-subject variability of striatum size. Furthermore, it might be more sensitive to errors of the estimate of non-displaceable FP-CIT binding. This study compared SUSI and SBR in the multi-site/multi-camera (MULTI) setting of a prospective multi-center study and in a mono-site/mono-camera (MONO) setting representative of clinical routine. The MULTI setting included patients with Parkinson’s disease (PD, n = 438) and healthy controls (n = 207) from the Parkinson Progression Marker Initiative. The MONO setting included 122 patients from routine clinical patient care in whom FP-CIT SPECT had been performed with the same double-head SPECT system according to the same acquisition and reconstruction protocol. Patients were categorized as “neurodegenerative” (n = 84) or “non-neurodegenerative” (n = 38) based on follow-up data. FP-CIT SPECTs were stereotactically normalized to MNI space. SUSI and SBR were computed for caudate, putamen, and whole striatum using unilateral ROIs predefined in MNI space. SUSI analysis was repeated in native patient space in the MONO setting. The area (AUC) under the ROC curve for identification of PD/“neurodegenerative” cases was used as performance measure. In both settings, the highest AUC was achieved by the putamen (minimum over both hemispheres), independent of the semi-quantitative method (SUSI or SBR). The putaminal SUSI provided slightly better performance with ROI analysis in MNI space compared to patient space (AUC = 0.969 vs. 0.961, p = 0.129). The SUSI (computed in MNI space) performed slightly better than the SBR in the MULTI setting (AUC = 0.993 vs. 0.991, p = 0.207) and slightly worse in the MONO setting (AUC = 0.969 vs. AUC = 0.976, p = 0.259). There was a trend toward larger AUC difference between SUSI and SBR in the MULTI setting compared to the MONO setting (p = 0.073). Variability of voxel intensity in the reference region was larger in misclassified cases compared to correctly classified cases for both SUSI and SBR (MULTI setting: p = 0.007 and p = 0.012, respectively). The SUSI is particularly useful in MULTI settings. SPECT images should be stereotactically normalized prior to SUSI analysis. The putaminal SUSI provides better diagnostic performance than the SUSI of the whole striatum. Errors of the estimate of non-displaceable count density in the reference region can cause misclassification by both SUSI and SBR, particularly in borderline cases. These cases might be identified by visual checking FP-CIT uptake in the reference region for particularly high variability.
- Open Access
- 10 August 2018
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 46 (2) , 312-323
Amyloid imaging for differential diagnosis of dementia: incremental value compared to clinical diagnosis and [18F]FDG PET
Purpose Cerebral beta-amyloid and regional glucose metabolism assessed by positron emission tomography (PET) are used as diagnostic biomarkers for Alzheimer’s disease (AD). The present study validates the incremental diagnostic value of amyloid PET in addition to clinical diagnosis and [18F]FDG PET in a real-life memory clinic population. Methods Of 138 consecutive patients with cognitive impairment who received combined [18F]FDG and [11C]PIB PET, 84 were diagnosed with major neurocognitive disorder (DSM-5) and included. Baseline clinical and [18F]FDG PET diagnoses were independently established with and without access to amyloid PET results and were dichotomized into AD or non-AD disorders. The incremental value of amyloid PET was evaluated in terms of: (1) the change in clinical and [18F]FDG PET diagnoses, (2) the change in agreement between clinical and [18F]FDG PET diagnoses, and (3) diagnostic accuracy using an interdisciplinary consensus diagnosis after an extended follow-up (2.4 ± 1.3 years after PET) as the reference. Results After disclosure of the amyloid PET results, clinical and [18F]FDG PET diagnoses changed in 23% and 18% of patients, respectively, and agreement between both ratings increased from 62% to 86% (p < 0.001). The accuracy of clinical and [18F]FDG PET diagnoses improved from 71% to 89% (p < 0.01) and from 76% to 94% (p < 0.001), respectively. The additional value of amyloid PET was rather uniform in relation to age at onset and consistency with appropriate use criteria. Conclusion Amyloid PET provides significant incremental diagnostic value beyond clinical and [18F]FDG PET diagnoses of AD. Given the high diagnostic accuracy of combined clinical and amyloid PET assessment, further studies are needed to clarify the role of an additional [18F]FDG PET scan in these patients.
- 10 August 2018
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 46 (2) , 312-323
Open AccessAmyloid imaging for differential diagnosis of dementia: incremental value compared to clinical diagnosis and [18F]FDG PET
Purpose Cerebral beta-amyloid and regional glucose metabolism assessed by positron emission tomography (PET) are used as diagnostic biomarkers for Alzheimer’s disease (AD). The present study validates the incremental diagnostic value of amyloid PET in addition to clinical diagnosis and [18F]FDG PET in a real-life memory clinic population. Methods Of 138 consecutive patients with cognitive impairment who received combined [18F]FDG and [11C]PIB PET, 84 were diagnosed with major neurocognitive disorder (DSM-5) and included. Baseline clinical and [18F]FDG PET diagnoses were independently established with and without access to amyloid PET results and were dichotomized into AD or non-AD disorders. The incremental value of amyloid PET was evaluated in terms of: (1) the change in clinical and [18F]FDG PET diagnoses, (2) the change in agreement between clinical and [18F]FDG PET diagnoses, and (3) diagnostic accuracy using an interdisciplinary consensus diagnosis after an extended follow-up (2.4 ± 1.3 years after PET) as the reference. Results After disclosure of the amyloid PET results, clinical and [18F]FDG PET diagnoses changed in 23% and 18% of patients, respectively, and agreement between both ratings increased from 62% to 86% (p < 0.001). The accuracy of clinical and [18F]FDG PET diagnoses improved from 71% to 89% (p < 0.01) and from 76% to 94% (p < 0.001), respectively. The additional value of amyloid PET was rather uniform in relation to age at onset and consistency with appropriate use criteria. Conclusion Amyloid PET provides significant incremental diagnostic value beyond clinical and [18F]FDG PET diagnoses of AD. Given the high diagnostic accuracy of combined clinical and amyloid PET assessment, further studies are needed to clarify the role of an additional [18F]FDG PET scan in these patients.
- 23 February 2018
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 125 (6) , 995-1005
Antidepressant treatment effects on dopamine transporter availability in patients with major depression: a prospective 123I-FP-CIT SPECT imaging genetic study
We investigated if sleep deprivation (SD) and electroconvulsive therapy (ECT) affect striatal dopamine transporter (DAT) availability assessed by single-photon emission computed tomography (SPECT) and 123I-FP-CIT, if dopamine transporter gene (SLC6A3; DAT) variation modifies aforementioned parameters, and if SD response or SD-induced DAT changes correlate with ECT response. Sixteen patients with major depression (MDD) referred for ECT and 12 matched controls were prospectively recruited for imaging and SLC6A3 VNTR genotyping. After withdrawal from any psychiatric medication, 123I-FP-CIT-SPECT was acquired at baseline, after SD and after ECT series. Striatal DAT availability was assessed by volume-of-interest analysis of SPECT data. Eleven patients underwent combined treatment with SD and ECT (five ECT responders and six non-responders). Per-protocol analyses yielded no significant effect of SD or ECT on striatal DAT availability using repeated-measures ANOVA. However, intention-to-treat analysis indicated a significant decrease of striatal DAT availability due to SD (paired t test, p < 0.01). Stratification by SLC6A3 VNTR genotype suggested the 9R allele to drive this effect. In an exploratory analysis, SD-induced change in DAT availability of the left caudate nucleus predicted ECT response. This study revealed a treatment effect of SD on striatal DAT availability—possibly depending on SLC6A3 VNTR genotype. This and the observed association between SD-induced change of striatal DAT availability and response to ECT may help to identify treatment mechanisms and response predictors useful for precision medicine approaches in the treatment of MDD.
- 23 February 2018
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 125 (6) , 995-1005
Antidepressant treatment effects on dopamine transporter availability in patients with major depression: a prospective 123I-FP-CIT SPECT imaging genetic study
We investigated if sleep deprivation (SD) and electroconvulsive therapy (ECT) affect striatal dopamine transporter (DAT) availability assessed by single-photon emission computed tomography (SPECT) and 123I-FP-CIT, if dopamine transporter gene (SLC6A3; DAT) variation modifies aforementioned parameters, and if SD response or SD-induced DAT changes correlate with ECT response. Sixteen patients with major depression (MDD) referred for ECT and 12 matched controls were prospectively recruited for imaging and SLC6A3 VNTR genotyping. After withdrawal from any psychiatric medication, 123I-FP-CIT-SPECT was acquired at baseline, after SD and after ECT series. Striatal DAT availability was assessed by volume-of-interest analysis of SPECT data. Eleven patients underwent combined treatment with SD and ECT (five ECT responders and six non-responders). Per-protocol analyses yielded no significant effect of SD or ECT on striatal DAT availability using repeated-measures ANOVA. However, intention-to-treat analysis indicated a significant decrease of striatal DAT availability due to SD (paired t test, p < 0.01). Stratification by SLC6A3 VNTR genotype suggested the 9R allele to drive this effect. In an exploratory analysis, SD-induced change in DAT availability of the left caudate nucleus predicted ECT response. This study revealed a treatment effect of SD on striatal DAT availability—possibly depending on SLC6A3 VNTR genotype. This and the observed association between SD-induced change of striatal DAT availability and response to ECT may help to identify treatment mechanisms and response predictors useful for precision medicine approaches in the treatment of MDD.
- Open Access
- 7 December 2017
- Published by Springer Nature in Fluids and Barriers of the CNS
- Vol. 14 (1) , 1-8
Do patients with schizophreniform and bipolar disorders show an intrathecal, polyspecific, antiviral immune response? A pilot study
We previously described inflammatory cerebrospinal fluid (CSF) alterations in a subgroup of patients with schizophreniform disorders and the synthesis of polyspecific intrathecal antibodies against different neurotropic infectious pathogens in some patients with bipolar disorders. Consequently, we have measured the prevalence of a positive MRZ reaction (MRZR)—a marker for a polyspecific, antiviral, intrathecal, humoral immune response composed of three antibody indices for the neurotropic viruses of measles (M), rubella (R), and varicella zoster (Z)—in these patients. We analyzed paired CSF and serum samples of 39 schizophreniform and 39 bipolar patients. For comparison, we used a group of 48 patients with other inflammatory neurological disorders (OIND) and a cohort of 203 multiple sclerosis (MS) patients. We found a positive MRZR in two patients with schizophreniform disorders (5.1%); both suffered from schizodepressive disorders without any other signs suggestive of MS. None of the bipolar patients (0%) and four members of the OIND group (8.3%) showed a positive MRZR. In the MS cohort, a positive MRZR was found significantly more frequently [in 99 patients (48.8%)] than in the other patient groups (p > 0.001). In summary, we did not find a positive MRZR in a relevant subgroup of patients with schizophreniform or bipolar disorders. Our results indicate that the MRZR is highly specific to MS. Nevertheless, two schizodepressive patients also had a positive MRZR. This finding corresponds to the few MRZR-positive patients with OIND or other autoimmune disorders with central nervous involvement, implicating that the MRZR specificity for MS is high, but not 100%.
- 7 December 2017
- Published by Springer Nature in Fluids and Barriers of the CNS
- Vol. 14 (1) , 1-8
Open AccessDo patients with schizophreniform and bipolar disorders show an intrathecal, polyspecific, antiviral immune response? A pilot study
We previously described inflammatory cerebrospinal fluid (CSF) alterations in a subgroup of patients with schizophreniform disorders and the synthesis of polyspecific intrathecal antibodies against different neurotropic infectious pathogens in some patients with bipolar disorders. Consequently, we have measured the prevalence of a positive MRZ reaction (MRZR)—a marker for a polyspecific, antiviral, intrathecal, humoral immune response composed of three antibody indices for the neurotropic viruses of measles (M), rubella (R), and varicella zoster (Z)—in these patients. We analyzed paired CSF and serum samples of 39 schizophreniform and 39 bipolar patients. For comparison, we used a group of 48 patients with other inflammatory neurological disorders (OIND) and a cohort of 203 multiple sclerosis (MS) patients. We found a positive MRZR in two patients with schizophreniform disorders (5.1%); both suffered from schizodepressive disorders without any other signs suggestive of MS. None of the bipolar patients (0%) and four members of the OIND group (8.3%) showed a positive MRZR. In the MS cohort, a positive MRZR was found significantly more frequently [in 99 patients (48.8%)] than in the other patient groups (p > 0.001). In summary, we did not find a positive MRZR in a relevant subgroup of patients with schizophreniform or bipolar disorders. Our results indicate that the MRZR is highly specific to MS. Nevertheless, two schizodepressive patients also had a positive MRZR. This finding corresponds to the few MRZR-positive patients with OIND or other autoimmune disorders with central nervous involvement, implicating that the MRZR specificity for MS is high, but not 100%.
- 1 July 2016
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 55, 126-137
Altered microglia morphology and higher resilience to stress-induced depression-like behavior in CX3CR1-deficient mice
- 1 July 2016
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 55, 126-137
Altered microglia morphology and higher resilience to stress-induced depression-like behavior in CX3CR1-deficient mice